Navigation Links
Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
Date:9/9/2010

Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference -- POINT RICHMOND, Calif., Sept. 9 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Trade Show News Click to view news release full screen  

Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference

 

POINT RICHMOND, Calif., Sept. 9 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present a general business overview at the UBS Global Life Sciences Conference in New York on September 20, 2010 at 8:00 a.m. EDT.

A live audio webcast and replay of this presentation may be accessed at http://cc.talkpoint.com/ubsx001/092110a_lv/?entity=8_GI5K5ME and on the Transcept Investor webpage at www.transcept.com.

About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. Transcept is also developing TO-2061, an ultra low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with SSRIs. Transcept plans to begin a Phase 2 study of TO-2061 in 2011. For further information, please visit the Transcept website at: www.transcept.com.Contact:Transcept Pharmaceuticals, Inc.Greg MannDirector, Corporate Communications(510) 215-3567gmann@transcept.com
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
2. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
3. Transcept Pharmaceuticals to Report First Quarter 2009 Results
4. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
5. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
6. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
7. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
8. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
9. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
10. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)... PUNE, India , February 5, 2016 ... to a new market research report "Fetal (Labor & ... (Intrapartum & Antepartum), Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management ... 2020", published by MarketsandMarkets, This report studies the global ... The market is estimated at USD 6.28 Billion in ...
(Date:2/5/2016)... -- France , Germany , ... Israel ). It includes a 10-year epidemiology forecast for ... by age and sex in these markets. GD epidemiology report is written ... high quality, transparent and market-driven, providing expert analysis of disease trends in ... , Italy , Spain , ...
Breaking Medicine Technology:
(Date:2/5/2016)... Ontario (PRWEB) , ... February 05, 2016 , ... After ... Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to ... Scarborough Hospital. He successfully completed his first three-year term as chief and began a ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to ... may be safer than regular municipal or well water. The recent experience with lead ... Kleyne, could go a long way toward increasing public acceptance of recycled waste water ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... in the 2015 Best in KLAS: Software & Services for HIT Implementation Support ... in KLAS report independently ranks vendor performance by healthcare executives, managers and clinicians ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, Dr. ... Cheng, CitiDent offers a complete range of oral health care, including general dentistry, ...
(Date:2/5/2016)... ... February 05, 2016 , ... California Mobile Kitchens , ... of their latest mobile kitchen model, featuring customizable stainless steel interiors and a ... kitchens for use anywhere in the U.S. Many of their units can be ...
Breaking Medicine News(10 mins):